Evidence map›Paper›PMID 26970778›Full record

ArticleLipids in health and disease2016

Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer.

Vidar G Flote, Riyas Vettukattil, Tone F Bathen, Thore Egeland, Anne McTiernan, Hanne Frydenberg, Anders Husøy, Sissi E Finstad, Jon Lømo, Øystein Garred and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Lipids in health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. MR spectroscopy in breast cancer metabolomics.Analytical science advances · 2021
    Review
  14. Cancers · 2021
    Article
  15. Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer.International journal of molecular sciences · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Vidar G FloteThe Cancer Centre, Oslo University Hospital HF, N-0424, Oslo, Norway. v.g.flote@medisin.uio.no.ORCID http://orcid.org/0000-0003-2107-0692
Riyas VettukattilDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Tone F BathenDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Thore EgelandDepartment of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, N-1432, Aas, Norway.
Anne McTiernanPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hanne FrydenbergThe Cancer Centre, Oslo University Hospital HF, N-0424, Oslo, Norway.
Anders HusøyThe Cancer Centre, Oslo University Hospital HF, N-0424, Oslo, Norway.
Sissi E FinstadNorwegian Directorate of Health, PO Box 7000, St. Olavs plass, N-0130, Oslo, Norway.
Jon LømoDepartment of Pathology, Oslo University Hospital, N-0424, Oslo, Norway.
Øystein GarredDepartment of Pathology, Oslo University Hospital, N-0424, Oslo, Norway.
Ellen SchlichtingDepartment of Breast and Endocrine Surgery, Oslo University Hospital, N-0424, Oslo, Norway.
Erik A WistThe Cancer Centre, Oslo University Hospital HF, N-0424, Oslo, Norway.
Inger ThuneThe Cancer Centre, Oslo University Hospital HF, N-0424, Oslo, Norway.
Oslo University Hospital · NONorwegian University of Science and Technology · NOFred Hutch Cancer Center · USNorwegian Directorate of Health · NONorwegian University of Life Sciences · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-Density Lipoprotein (HDL)-cholesterol, has been associated with breast cancer development, but the association is under debate, and whether lipoprotein subfractions is associated with breast tumor characteristics remains unclear.

methodsAmong 56 women with newly diagnosed invasive breast cancer stage I/II, aged 35-75 years, pre-surgery overnight fasting serum concentrations of lipids were assessed, and body mass index (BMI) was measured. All breast tumors were immunohistochemically examined in the surgical specimen. Serum metabolomics of lipoprotein subfractions and their contents of cholesterol, free cholesterol, phospholipids, apolipoprotein-A1 and apolipoprotein-A2, were assessed using nuclear magnetic resonance. Principal component analysis, partial least square analysis, and uni- and multivariable linear regression models were used to study whether lipoprotein subfractions were associated with breast cancer tumor characteristics.

resultsThe breast cancer patients had following means: age at diagnosis: 55.1 years; BMI: 25.1 kg/m(2); total-Cholesterol: 5.74 mmol/L; HDL-Cholesterol: 1.78 mmol/L; Low-Density Lipoprotein (LDL)-Cholesterol: 3.45 mmol/L; triglycerides: 1.18 mmol/L. The mean tumor size was 16.4 mm, and the mean Ki67 hotspot index was 26.5%. Most (93%) of the patients had estrogen receptor (ER) positive tumors (≥ 1% ER+), and 82% had progesterone receptor (PgR) positive tumors (≥ 10% PgR+). Several HDL subfraction contents were strongly associated with PgR expression: Apolipoprotein-A1 (β 0.46, CI 0.22-0.69, p < 0.001), HDL cholesterol (β 0.95, CI 0.51-1.39, p < 0.001), HDL free cholesterol (β 2.88, CI 1.28-4.48, p = 0.001), HDL phospholipids (β 0.70, CI 0.36-1.04, p < 0.001). Similar results were observed for the subfractions of HDL1-3. We observed inverse associations between HDL phospholipids and Ki67 (β -0.25, p = 0.008), and in particular between HDL1's contents of cholesterol, phospholipids, apolipoprotein-A1, apolipoprotein-A2 and Ki67. No association was observed between lipoproteins and ER expression.

conclusionOur findings hypothesize associations between different lipoprotein subfractions, and PgR expression, and Ki 67 % in breast tumors. These findings may have clinical implications, but require confirmation in larger studies.

Indexed as

AdultAgedApolipoprotein A-IApolipoprotein A-IIBreast NeoplasmsCholesterolCholesterol, HDLFemaleHumansLipoproteinsMagnetic Resonance SpectroscopyMiddle AgedPrincipal Component AnalysisTriglyceridesAPOA1 protein, humanAPOA2 protein, humanApolipoprotein A-IApolipoprotein A-IICholesterolCholesterol, HDLLipoproteinsTriglyceridesBreast cancerHDLKi67LipoproteinsProgesterone receptorSubfractionsTumor

Identifiers

PMID26970778
PMCPMC4789271
OpenAlexW2293622675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.